Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

253.39
+2.480.99%
Volume:1.87M
Turnover:471.46M
Market Cap:447.83B
PE:71.58
High:254.40
Open:251.23
Low:249.74
Close:250.91
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.49
T/O Rate:0.11%
Dividend:6.83
Dividend Rate:2.70%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-75.46
PE(LYR):107.37

Loading ...

Plastic Surgery is Booming with Boomers. Here's How to Cash in on the Antiaging Craze.

Dow Jones
·
Sep 05

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

TIPRANKS
·
Sep 04

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Sep 04

AbbVie Closes $10.9B Apogee Deal — Accretion Not Until 2032

Bellwether Stocks Movement
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Sep 03

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Reuters
·
Sep 03

Abbvie Completes Acquisition of Apogee Therapeutics

THOMSON REUTERS
·
Sep 03

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS
·
Sep 03

AbbVie to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03